Dermatology

Dermatology Diagnostic Devices and Therapeutics Market Trends 2026: AI-Powered Skin Screening, Advanced Imaging and Next-Generation Treatment Solutions

24LifeScience Market Intelligence

Dermatology is no longer limited to treating visible skin conditions such as acne, eczema and psoriasis. The specialty increasingly involves early cancer recognition, chronic inflammatory disease management, digital patient monitoring and precision-based treatment. According to the World Health Organization's June 2026 draft Global Action Plan on Skin Diseases 2026-2035, approximately 4.69 billion incident cases of skin diseases occur annually worldwide. The document also highlights the effects of skin disorders on disability, mental well-being, productivity and access to healthcare.  

  • This growing clinical burden is bringing diagnostic technologies and therapeutic products closer together.  

  • Dermoscopy, digital skin imaging, optical diagnostic equipment, biopsy-assistance technologies and advanced pharmaceutical treatments are becoming important components of dermatological care.  

  • The focus is shifting from identifying a skin abnormality after symptoms become prominent towards recognizing disease earlier and selecting treatment according to individual clinical requirements. 

AI-Assisted Skin Examination Moves beyond Conventional Dermoscopy 

Artificial intelligence is creating new possibilities in the interpretation of skin images. Conventional dermoscopy remains an important examination method, but AI-assisted systems can evaluate image characteristics and provide additional information when clinicians assess suspicious lesions. 

A significant clinical development appeared in August 2026, when JAMA Dermatology published research examining AI-assisted line-field confocal optical coherence tomography (LC-OCT) for detecting subclinical basal cell carcinoma. The feasibility study involved 150 patients at increased risk of basal cell carcinoma. Investigators identified histologically confirmed subclinical cancers in 14 patients, representing 9.3% of participants, with a positive predictive value of 83.3%. The findings indicate potential applications in high-risk patient monitoring, although further research is needed to establish clinical benefits.  

The development is particularly relevant to dermatology diagnostic equipment manufacturers because it demonstrates how optical imaging and intelligent image interpretation can work together. However, AI remains an adjunct to professional assessment rather than a replacement for clinical examination or histopathological confirmation. 

Optical Imaging Creates New Possibilities for Biopsy Decisions 

  • Reflectance confocal microscopy (RCM), optical coherence tomography (OCT) and LC-OCT are expanding the range of non-invasive examination methods available to dermatologists. These technologies provide information about skin structures at different depths and can help specialists evaluate lesions before deciding whether tissue sampling is necessary. 

  • A 2026 scoping review published in the Journal of Investigative Dermatology examined 114 diagnostic-accuracy studies covering 11 non-invasive imaging modalities for melanoma detection. The technologies included dermoscopy, RCM, OCT-based imaging, multispectral imaging, high-frequency ultrasound and Raman spectroscopy. The review illustrates how dermatology diagnostics are developing beyond conventional photographic examination.  

  • Another study published in the International Journal of Dermatology in August 2026 compared RCM and LC-OCT in 100 facial and scalp lesions suspicious for basal cell carcinoma. Expert readers recorded mean sensitivity of 95.7% for RCM and 86.2% for LC-OCT. The research highlights the importance of selecting appropriate imaging methods according to lesion characteristics and clinical requirements.  

FDA Regulation Gives AI-Based Skin Diagnostics a Defined Clinical Role 

The regulatory environment is becoming increasingly important as software-assisted dermatology devices enter clinical practice. In March 2026, the US Food and Drug Administration established specific Class II regulatory requirements for optical diagnostic devices used in melanoma assessment. These devices are intended to provide additional information to qualified physicians evaluating suspicious lesions, rather than independently confirming cancer diagnoses.  

The FDA also maintains a separate classification for software-aided adjunctive diagnostic devices that analyse optical or other physical characteristics of suspicious skin lesions. This regulatory distinction matters because manufacturers must demonstrate appropriate clinical performance and define the intended use of their technologies.  

For healthcare providers, this creates a clearer distinction between consumer skin-analysis applications and clinically regulated diagnostic equipment. 

To find out more, feel free to browse our latest updated report: https://www.24lifesciences.com/dermatology-diagnostic-devices-and-therapeutics-market-9455 

Psoriasis and Atopic Dermatitis Treatments Enter a New Phase 

The therapeutic side of dermatology is experiencing equally important developments. Biologics, targeted immunomodulators and advanced topical formulations are changing treatment approaches for patients with persistent inflammatory skin disorders. 

  • In September 2026, the European Medicines Agency recorded the EU marketing authorisation of Icotyde (icotrokinra), an oral treatment for moderate-to-severe plaque psoriasis in eligible adults and adolescents.  

  • The medicine targets the interleukin-23 receptor, offering a different therapeutic approach from conventional topical treatments.  

  • Its clinical programme included approximately 2,500 patients, and three major studies reported PASI 90 responses in 50%-57% of patients receiving the medicine after 16 weeks.  

Another notable development came from the United States in June 2026, when the FDA approved an every-eight-week maintenance dosing option for Eli Lilly's EBGLYSS (lebrikizumab) in eligible patients with moderate-to-severe atopic dermatitis. The revised regimen offers the possibility of as few as six maintenance injections annually.  

These developments illustrate how treatment innovation is increasingly considering disease control alongside administration frequency, patient convenience and long-term management. 

Digital Dermatology Connects Specialist Care with Remote Monitoring 

Teledermatology is becoming an important part of healthcare delivery, particularly where access to dermatologists is limited. Digital photography, secure image transfers, video consultations and remote follow-ups allow healthcare professionals to assess selected skin conditions without requiring every patient to attend an in-person appointment. 

Recent developments in digital dermatology also involve mobile applications, automated lesion assessment and patient-monitoring platforms. These technologies can support treatment adherence and help clinicians compare changes in skin conditions over time. However, image quality, patient privacy, data interoperability and differences in skin pigmentation remain important considerations when introducing digital diagnostic systems into routine healthcare.  

Skin-Tone Representation Becomes Essential for Diagnostic Accuracy 

  • One important consideration for dermatology device manufacturers is whether diagnostic technologies perform consistently across different skin tones. AI systems trained predominantly on lighter skin images may produce less reliable results when assessing patients with darker pigmentation. 

  • A 2026 systematic review examining AI-based skin-lesion diagnosis reported differences in diagnostic performance across skin-tone categories. Its findings reinforce the importance of representative clinical datasets, external validation and appropriate reporting of diagnostic accuracy across patient populations.  

  • This issue has practical implications for manufacturers developing smartphone-based skin analysis, dermoscopic imaging equipment and automated diagnostic software. Clinical reliability must extend beyond impressive laboratory results to reflect the diversity of patients encountered in everyday dermatology practice. 

The Convergence of Diagnosis and Treatment Is Reshaping Skin Healthcare 

The most important development across dermatology is the closer integration of diagnostic information and therapeutic decision-making. Advanced imaging can help clinicians characterize suspicious lesions, while targeted medicines provide additional treatment options for chronic inflammatory conditions. 

As healthcare systems expand access to dermatological services, opportunities are emerging across dermoscopy equipment, optical imaging systems, digital diagnostic platforms, biopsy-assistance devices, biologics and prescription topical formulations. The next stage of dermatology innovation will depend on how effectively these technologies translate clinical evidence into accessible, safe and consistent patient care.